इम्यूनोथेरेपी: ओपन एक्सेस
खुला एक्सेस

अमूर्त

Bispecific Antibody Goes to Hybrid

Aifen Li, Li Li, Qing Li and Zhong Wang

Bispecific antibody has being actively pursued in cancer immunotherapy. By binding to specific surface proteins on T cells or NK cells, bispecific antibodies recruit T cells or NK cells to close proximity of tumor cells and kill tumor cells. A number of bispecific antibodies with diverse formats have been developed and some of them already in clinical stages. In the study of “Her2-S-Fab bispecific antibody has potent cytotoxicity against Her2-expressing tumor cells”, a novel format of bispecific antibody was reported. Here we briefly describe this study and its implications in cancer immunotherapy.